Provectus Biopharmaceuticals (NYSEMKT: PVCT ) resumed trading today, but shareholders probably wished it was still frozen from last Friday. Shares collapsed a startling 63% on news that the FDA would not grant a breakthrough designation to Provectus' melanoma drug PV-10.
In this episode of Market Checkup, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss the controversy surrounding Provectus, the increasing competition for its mid-stage drug, and whthere the stock is a bad news buy.
Watch and find out.
Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.